Georg Semmler
A5067605507- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis C virus research
- Organ Transplantation Techniques and Outcomes
- Liver Diseases and Immunity
- Hepatocellular Carcinoma Treatment and Prognosis
- Alcohol Consumption and Health Effects
- Diet, Metabolism, and Disease
- Hepatitis B Virus Studies
- Colorectal Cancer Screening and Detection
- Drug-Induced Hepatotoxicity and Protection
- Eosinophilic Esophagitis
- Gastroesophageal reflux and treatments
- Helicobacter pylori-related gastroenterology studies
- Hormonal Regulation and Hypertension
- Hepatitis Viruses Studies and Epidemiology
- COVID-19 Clinical Research Studies
- Diet and metabolism studies
- Gastric Cancer Management and Outcomes
- Trace Elements in Health
- Pancreatitis Pathology and Treatment
- Growth Hormone and Insulin-like Growth Factors
- SARS-CoV-2 and COVID-19 Research
- Nutrition and Health in Aging
- Diverticular Disease and Complications
Medical University of Vienna
2018-2025
Odense University Hospital
2025
University of Southern Denmark
2025
Montavid Thermodynamic Research Group
2025
Paracelsus Medical University
2020-2023
University of Bologna
2023
University of Modena and Reggio Emilia
2023
ERN GUARD-Heart
2022
Krankenhaus Oberndorf
2020-2022
University of Milan
2022
INTRODUCTION: We aimed to explore the prevalence of portal hypertension in most common etiologies patients with compensated advanced chronic liver disease (cACLD) and develop classification rules, based on stiffness measurement (LSM), that could be readily used diagnose or exclude clinically significant (CSPH) clinical practice. METHODS: This is an international cohort study including paired LSM/hepatic venous pressure gradient (HVPG), LSM ≥10 kPa, no previous decompensation. Portal was...
Sustained virologic response (SVR) to interferon (IFN)-free therapies ameliorates portal hypertension (PH); however, it remains unclear whether a decrease in hepatic venous pressure gradient (HVPG) after cure of hepatitis C translates into clinical benefit. We assessed the impact pretreatment HVPG, changes and posttreatment HVPG on development decompensation patients with PH who achieved SVR IFN-free therapy. Moreover, we evaluated transient elastography (TE) von Willebrand factor platelet...
Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality in patients with advanced chronic liver disease (ACLD) caused by hepatitis C who have achieved sustained virologic response (SVR). We developed risk stratification algorithms for de novo HCC development after SVR validated them an independent cohort.We evaluated the occurrence derivation cohort 527 pre-treatment ACLD to interferon-free therapy, whom alpha-fetoprotein (AFP) non-invasive surrogates portal hypertension...
Liver stiffness measurements (LSMs) provide an opportunity to monitor liver disease progression and regression noninvasively. We aimed determine the prognostic relevance of LSM dynamics over time for liver-related events death in patients with chronic disease.Patients undergoing 2 or more reliable LSMs at least 180 days apart were included this retrospective cohort study stratified baseline (BL) as nonadvanced (non-ACLD, BL-LSM < 10 kPa), compensated ACLD (cACLD; ≥ decompensated ACLD. Data...
Abstract Background and Aims Cholestasis is associated with disease severity worse outcome in COVID‐19. Cases of secondary sclerosing cholangitis (SSC) after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection have been described. Approach Results Hospitalized patients COVID‐19 between 03/2020 07/2021 were included. Patients stratified as having (i) no chronic liver (CLD), (ii) non‐advanced CLD (non‐ACLD), or (iii) advanced (ACLD). non–COVID‐19 pneumonia matched to a...
Baveno VII proposed liver stiffness measurement (LSM)/platelet count (PLT)-based criteria ('ruled out,' LSM ≤15 kPa plus PLT ≥150 G/L; 'ruled in': ≥25 kPa) for clinically significant portal hypertension (CSPH) in compensated advanced chronic disease (cACLD). However, a substantial proportion of patients remains 'unclassified.'Patients with evidence cACLD (LSM ≥10 undergoing hepatic venous pressure gradient (HVPG) at the Vienna General Hospital 2004 to 2021 (derivation [2004-2016], n = 221;...
Although ascites is the most frequent first decompensating event in cirrhosis, clinical course after as
Metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed to replace non-alcoholic fatty and focus on patients with progressive due the presence of metabolic dysfunction. However, it is unclear whether new definition actually identifies hepatic steatosis at increased cardiovascular risk.
Removing the primary aetiological factor in decompensated cirrhosis may lead to a restoration of hepatic function. In this study, we investigated clinical implications recompensation and subsequent survival patients with alcohol-related cirrhosis.The rate was evaluated persistent alcohol abstinence undergoing venous pressure gradient (HVPG) measurement. Recompensation defined according Baveno VII criteria as resolution ascites encephalopathy, absence variceal bleeding improvement liver...
The Billroth IV consensus was developed during a meeting of the Austrian Society Gastroenterology and Hepatology (ÖGGH) Interventional Radiology (ÖGIR) held on 26th November 2022 in Vienna.Based international recommendations considering recent landmark studies, provides guidance regarding diagnosis management portal hypertension advanced chronic liver disease.
Background & Aims Liver stiffness measurements (LSM) are recommended for disease prognostication and monitoring. We evaluated if LSM, using transient elastography, LSM changes predict decompensation mortality in patients with alcohol-related liver (ALD). Methods Observational cohort study of compensated at risk ALD from Denmark Austria. the all-cause mortality, stratified advanced chronic (cACLD: Baseline ≥10 kPa) after a median 2 years. In cACLD, we defined as (A) increase ≥20% ("cACLD...
Background and AimsNon-invasive tests (NIT) for assessing the probability of clinically significant portal hypertension (CSPH) including ANTICIPATE±NASH models based on liver stiffness measurement (LSM), platelet count (PLT)±body mass index (BMI), von Willebrand factor antigen (VWF) to PLT ratio (VITRO) have fundamentally changed management compensated advanced chronic disease (cACLD). However, their prognostic utility has not been compared head-to-head against hepatic venous pressure...
Baveno VII has defined a clinically significant (i.e., prognostically meaningful) decrease in liver stiffness measurement (LSM) cACLD as of ≥20% associated with final LSM <20 kPa or any to <10 kPa. However, these rules have not yet been validated against direct clinical endpoints.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of advanced chronic (ACLD). Portal hypertension drives hepatic decompensation and best diagnosed by venous pressure gradient (HVPG) measurement. Here, we investigate the prognostic value HVPG in MASLD-related compensated ACLD (MASLD-cACLD).
Summary Background and Aims The prognostic performance of von Willebrand factor (VWF) may vary across clinical stages advanced chronic liver disease (ACLD). Therefore, we investigated the evolution VWF other biomarkers throughout full ACLD spectrum evaluated their stage‐specific utility. Methods We retrospectively included Viennese patients with available information on hepatic venous pressure gradient (HVPG), C‐reactive protein (CRP)/VWF levels outcomes. were defined according to D'Amico et...
Tangier disease (TD) is a rare, autosomal recessive genetic disorder associated with deficiency in cellular cholesterol export leading to accumulation peripheral tissues. With approximately 150 described cases, the significantly understudied, and clinical presentation appears be heterogenous. To investigate phenotype lipid metabolism TD. Multicenter cohort study. Four patients Nuclear magnetic resonance (NMR)-based lipidomic metabolomic analyses were performed TD healthy controls. While...
Abstract Background Anaemia is common in advanced chronic liver disease (ACLD) as a result of various risk factors. Aims & Methods We evaluated the prevalence and severity anaemia well impact on clinical outcomes consecutive patients with ACLD portal hypertension. Results Among 494 patients, 324 (66%) had anaemia. Anaemic showed higher MELD (12 ± 4 vs 9 3; P < .001), lower albumin (34 6 39 5 g/dL; .001) more often Child‐Pugh B/C stage (56% 17%; .001). The moderate‐severe (haemoglobin...
Background Gadoxetic acid-enhanced MRI enables estimation of liver function in patients with chronic disease (CLD). The functional imaging score (FLIS), derived from gadoxetic MRI, has been shown to predict transplant-free survival transplant patients. Purpose To investigate the accuracy FLIS for predicting hepatic decompensation and CLD. Materials Methods Patients CLD who had undergone including T1-weighted volume-interpolated breath-hold examination sequences fat suppression, performed...
Risk stratification after cure from hepatitis C virus (HCV) infection remains a clinical challenge. We investigated the predictive value of noninvasive surrogates portal hypertension (liver stiffness measurement [LSM] by vibration-controlled transient elastography and von Willebrand factor/platelet count ratio [VITRO]) for development hepatic decompensation hepatocellular carcinoma in patients with pretreatment advanced chronic liver disease (ACLD) who achieved HCV cure.